Ben Venue manufacturing difficulties spell delays for Clavis' Phase III CLAVELA trial
This article was originally published in Scrip
Executive Summary
Clavis Pharma has said that the top-line results from its Phase III CLAVELA trial in patients with late-stage acute myeloid leukaemia (AML) will be delayed by three months due to a shortage of the investigational drug elacytarabine, caused by problems with its present manufacturer, Ben Venue Laboratories. The data are now expected in the first quarter of 2013.